P2.01-22 ORCHARD: A Phase II Platform Study in Patients with Advanced NSCLC Who Have Progressed on First-Line Osimertinib TherapyHelena A. Yu, Jonathan W. Riess, Peter J. Smith et al.|Journal of Thoracic Oncology|2019Cited by 26
1O: Osimertinib (osi) + datopotamab deruxtecan (Dato-DXd) in patients (pts) with EGFR-mutated (EGFRm) advanced NSCLC (aNSCLC) whose disease progressed on first-line (1L) osi: ORCHARDX. Le, Sarah B. Goldberg, L. Hendriks et al.|Journal of Thoracic Oncology|2025Cited by 22